The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Prevention of 6-hydroxydopamine-induced rotational behavior by BDNF somatic gene transfer
Abstract
Brain-derived neurotrophic factor (BDNF) was expressed via injection of viral vector into the substantia nigra pars compacta (SNc) to investigate its influence on nigrostriatal dopaminergic activity and locomotor behavior. The recombinant adeno-associated virus (rAAV) vector, pTR-BDNFmyc, incorporated the neuron-specific enolase (NSE) promoter and the internal ribosome entry site (IRES) element driving expression of both epitope-tagged BDNF and green fluorescent protein (GFP) bicistronically. The control vector, pTR-UF4, incorporated NSE promoter-driven GFP expression only. Transgene expression persisted in both vector groups throughout the 9 month course of the study. Partial 6-hydroxydopamine (6-OHDA) lesions were conducted in the SNc ipsilateral to, and 6 months after, transduction with either the pTR-BDNFmyc or the pTR-UF4. Transgenic BDNFmyc had no effect on the number of tyrosine hydroxylase (TH)-labeled neurons in the SNc after 6-OHDA-lesions, but did block the amphetamine-induced, ipsiversive, turning-behavior caused by the lesion in the pTR-UF4 group. The BDNFmyc-transduced group also demonstrated more locomotor activity and rotational activity contralateral to the lesioned side than did the pTR-UF4-transduced group. Long-term, stable expression of BDNF can therefore modulate locomotor activity without significantly affecting nigrostriatal dopaminergic survival.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In the vast majority of studies with BDNF administration before induction of parkinsonism, the research results revealed at least partial prevention of neuronal cell loss [89,90,92,93,99,101].”
From BDNF as a Promising Therapeutic Agent in Parkinson’s Disease (2020) · cites this paper as [90]
In the citing paper
“However, the reports are not consistent; some have shown no increase in neuronal survival when BDNF was applied before intoxication with 6-hydroxydopamine (6-OHDA) in PD animal model [90,91].”
From BDNF as a Promising Therapeutic Agent in Parkinson’s Disease (2020) · cites this paper as [90]
Citations
Cites
The Rat Brain in Stereotaxic Coordinates
Paxinos, G., & Watson, C. (1983) · Elsevier eBooks · doi:10.1016/c2009-0-63235-9 · Cited by 28,585
Xiao, X., Li, J., & Samulski, R. J. (1998) · Journal of Virology · doi:10.1128/jvi.72.3.2224-2232.1998 · Cited by 1,381
Kaplitt, M. G., Leone, P., Samulski, R. J., Xiao, X., Pfaff, D. W., O’Malley, K. L., & During, M. J. (1994) · Nature Genetics · doi:10.1038/ng1094-148 · Cited by 1,031
Maisonpierre, P. C., Beau, M. M. L., Espinosa, R., Ip, N. Y., Belluscio, L., de la Monte, S. M., Squinto, S. P., Furth, M. E., & Yancopoulos, G. D. (1991) · Genomics · doi:10.1016/0888-7543(91)90436-i · Cited by 514
McCown, T. J., Xiao, X., Li, J., Breese, G. R., & Samulski, R. J. (1996) · Brain Research · doi:10.1016/0006-8993(95)01488-8 · Cited by 450
Forss‐Petter, S., Danielson, P. E., Catsicas, S., Battenberg, E., Price, J. A., Nerenberg, M. I., & Sutcliffe, G. (1990) · Neuron · doi:10.1016/0896-6273(90)90308-3 · Cited by 368
Mandel, R. J., Spratt, S. K., Snyder, R. O., & Leff, S. E. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.25.14083 · Cited by 328
Peel, A., Zolotukhin, S., Schrimsher, G. W., Muzyczka, N., & Reier, P. J. (1997) · Gene Therapy · doi:10.1038/sj.gt.3300358 · Cited by 289
Self-citationAltar, C. A., Boylan, C. B., Jackson, C., Hershenson, S., Miller, J., Wiegand, S. J., Lindsay, R. M., & Hyman, C. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.23.11347 · Cited by 275
Levivier, M., Przedborski, S., Bencsics, C., & Kang, U. (1995) · The Journal of Neuroscience · doi:10.1523/jneurosci.15-12-07810.1995 · Cited by 274
Cited by
Sorted by citations
Items 101–128 of 128
Gene therapeutic approaches to the treatment of Parkinson's disease
Bowers, W. J., Maguire‐Zeiss, K. A., Harvey, B. K., & Federoff, H. J. (2001) · Clinical Neuroscience Research · doi:10.1016/s1566-2772(01)00026-3 · Cited by 8
Current advances in combining stem cell and gene therapy for neurodegenerative diseases
Hwang, J.-Y., Won, J.-S., Nam, H., Lee, H. W., & Joo, K. M. (2018) · Precision and Future Medicine · doi:10.23838/pfm.2018.00037 · Cited by 7
Reporter genes for monitoring gene expression in mammalian cells
Alam, J., & Cook, J. L. (2003) · New comprehensive biochemistry · doi:10.1016/s0167-7306(03)38018-4 · Cited by 7
Hutson, T. H., Kathe, C., Menezes, S. C., Rooney, M.-C., Büeler, H., & Moon, L. D. F. (2014) · Methods in molecular biology · doi:10.1007/978-1-4939-0777-9_16 · Cited by 6
Gene Therapy for Parkinson’s Disease
Douglas, M., & Hazlehurst, J. (2011) · InTech eBooks · doi:10.5772/17420 · Cited by 4
Stem cells and regenerative therapies for Parkinson’s disease
Barker, R. A., & Farrell (2012) · Degenerative Neurological and Neuromuscular Disease · doi:10.2147/dnnd.s16087 · Cited by 5
Statz, M., Schleuter, F., Weber, H., Kober, M., Plocksties, F. V., Timmermann, D., Storch, A., & Fauser, M. (2023) · Neuroscience Letters · doi:10.1016/j.neulet.2023.137459 · Cited by 4
Neurotrophic factors and Parkinson's disease
Gash, D. M., Chen, Y., & Gerhardt, G. A. (2007) · Handbook of clinical neurology · doi:10.1016/s0072-9752(07)83025-9 · Cited by 3
The Causative and Curative Roles of Brain-Derived Neurotrophic Factor in Parkinson’s Disease
Hernández-Baltazar, D., Nadella, R., Llanderal, T. C., Puga-Olguín, A., Barrientos-Bonilla, A. A., Zavala-Flores, L. M., Villanueva-Olivo, A., Sánchez-García, A. D. C., Rovirosa-Hernández, M. D. J., & Rembao-Bojórquez, J. D. (2019) · IntechOpen eBooks · doi:10.5772/intechopen.81215 · Cited by 4
Gene Therapy with Virus Vectors for specific Disease of the Nervous System
Muramatsu, S., Wang, L., Ikeguchi, K., Fujimoto, K.-I., Nakano, I., Okada, T., Mizukami, H., Hanazono, Y., Kume, A., Nakano, I., et al. (2003) · International review of neurobiology · doi:10.1016/s0074-7742(03)01009-2 · Cited by 3
Clarke, E., Sinclair, L., Fletcher, E. J. R., Krawczun-Rygmaczewska, A., Duty, S., Stocki, P., Rutkowski, J. L., Doherty, P., & Walsh, F. S. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.03.12.987313 · Cited by 3
Lin, M.-S., Chen, S., Hua, K., Chen, W., Hsieh, C.-C., & Lin, C.-C. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11030553 · Cited by 2
Coculturing NSCs with Melanocyte Increased its Dopamine and Neural Factor Secretion
Chakraborty, A. K., & Diwan, A. R. (2021) · Acta Scientific Neurology · doi:10.31080/asne.2021.04.0315 · Cited by 2
Production and Application of Multicistronic Constructs for Various Human Disease Therapies
Shaimardonova, A. A., Chulpanova, D. S., Kitaeva, K. V., Abdrakhmanova, I. I., Chernov, V. M., Rutland, C. S., Rizvanov, A. A., & Solovyeva, V. V. (2021) · doi:10.1201/9781003180449-9 · Cited by 2
Design and Optimization of Expression Cassettes Including Promoter Choice and Regulatory Elements
Fitzsimons, H. L., & During, M. J. (2006) · Elsevier eBooks · doi:10.1016/b978-012397632-1/50002-2 · Cited by 2
Chakraborty, A. K., & Diwan, A. R. (2020) · Neurology and Neuroscience Reports · doi:10.15761/nnr.1000118 · Cited by 2
CNS Diseases Amenable to Gene Therapy
Federoff, H. J. (2003) · Springer eBooks · doi:10.1007/978-3-662-05352-2_9 · Cited by 2
Approaches in the treatment of Parkinson's disease : a focus on stem cell-based therapies.
Al-Maqtari, T. (2012) · ThinkIR: The University of Louisville's Institutional Repository (University of Louisville) · doi:10.18297/etd/34 · Cited by 1
Gene Therapy for Neurological Diseases
Bowers, W. J., & Federoff, H. J. (2003) · CRC Press eBooks · doi:10.1201/9780824758608.ch29 · Cited by 1
Goulding, S. R. (2021) · doi:10.34719/fhhg1227 · Cited by 1
Gene Therapy for Parkinson's Disease
Lawlor, P. A. (2006) · Elsevier eBooks · doi:10.1016/b978-012397632-1/50009-5
A role for the truncated trkB receptor in neurons
Fenner, B. M. (2004) · D-Scholarship@Pitt (University of Pittsburgh)
Generation of dopamine neurons in vivo and from embryonic stem cells in vitro
Friling, S. (2009) · Figshare
6-HYDROXYDOPAMINE NEUROTOXICITY DYSFUNCTION OF THE CREB SIGNALING PATHWAY DURING
Chalovich, E. M. (2006)
Lee, S.-H., Kwon, D., Yu, S., Koh, S., Park, M.-K., Kim, H., Park, K., & Lee, D.-H. (2003) · Journal of the Korean Neurological Association
Investigating chondroitin sulphate proteoglycans as a therapeutic target for Parkinson's disease
Fletcher, E. J. R. (2017) · Research Portal (King's College London)
SRY GENİNİN PARKİNSON HASTALIĞINDAKİ POTANSİYEL ROLÜNÜN İN SİLİKO ANALİZİ
Ay, M. (2022) · SDÜ Tıp Fakültesi Dergisi · doi:10.17343/sdutfd.1166918
Estrategias de transferencia génica en cerebro mediadas por vectores virales adenoasociados
Armas, J. M. B., Marrero, I. G., Perdomo, A. L. C., Calero, E. M. C., Fumero, A. A., Hernández, J. R. C., & Fuentes, R. (2009) · Majorensis: Revista Electrónica de Ciencia y Tecnología
Metadata
- Authors
- Klein, R. L., Lewis, M. H., Muzyczka, N., & Meyer, E. M.
- Affiliations
- University of Florida (US)
- Corresponding author
- Klein, Ronald L.
- ORCID
- Lewis, Mark H.
- Venue
- Brain Research
- Publisher
- Elsevier BV
- Published
- 1999-11
- Volume
- 847
- Issue
- 2
- Pages
- 314-320
- ISSN
- 0006-8993 (ISSN-L)
- OpenAlex
- W1987647111
- Cited by
- 128
- References
- 22
- Citations by year
- 2025: 1 · 2024: 1 · 2023: 2 · 2022: 7 · 2021: 4 · 2020: 5 · 2019: 3 · 2018: 5 · 2017: 3 · 2016: 3 · 2015: 4 · 2014: 4 · 2013: 4 · 2012: 6
- FWCI
- 4.02
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Brain Research (publishedVersion)
- PubMed (publishedVersion)
- Funders
- American Cancer Society
- National Institutes of Health (2r01gm035723-15)
- National Heart, Lung, and Blood Institute (HL 53665, HL/DK 50257, R01HL053665)
- National Institute of General Medical Sciences (GM35723)
- National Institute of Diabetes and Digestive and Kidney Diseases (R01DK050257)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Nerve injury and regeneration
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Keywords
- brain-derived neurotrophic factor, 6-hydroxydopamine lesion, substantia nigra pars compacta, gene transfer, adeno-associated virus vectors, neuron-specific enolase promoter, internal ribosome entry site, amphetamine-induced rotation, locomotor activity, dopaminergic neuron survival, tyrosine hydroxylase, neuroprotection
- MeSH terms
- Amphetamine, Central Nervous System Stimulants, Animals, Genetic Vectors, Humans, Motor Activity, Parkinson Disease, Substantia Nigra, Oxidopamine, Rats, Sprague-Dawley, Gene Transfer Techniques, Adrenergic Agents, Brain-Derived Neurotrophic Factor, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
